stockportfolio.pro
ANI Pharmaceuticals, Inc. (ANIP)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
ANI Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $128.62M | $176.84M | $201.58M | $206.55M | $208.47M | $216.14M | $316.38M | $486.82M | $614.38M | $883.37M |
| Gross profit | $79.84M | $97.81M | $128.55M | $143.39M | $121.32M | — | — | — | — | — |
| Net income | $3.93M | $-1.08M | $15.49M | $6.09M | $-22.55M | $-42.60M | $-49.52M | $17.15M | $-20.15M | $77.18M |
| Net margin | 3.1% | -0.6% | 7.7% | 3.0% | -10.8% | -19.7% | -15.7% | 3.5% | -3.3% | 8.7% |
Source: ANI Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of ANI Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANIP in your portfolio →
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s revenue?
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $883.37M for fiscal year 2025, up 43.8% from the prior year, according to its SEC filings.
Is ANI Pharmaceuticals, Inc. profitable?
Yes. ANIP earned net income of $77.18M in fiscal 2025, a net margin of 8.7%.
What is ANIP's P/E ratio?
ANI Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 20.8 based on the latest data in our nightly-refreshed cache.
How fast is ANI Pharmaceuticals, Inc. growing?
ANIP's revenue grew at roughly 33.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.